Wednesday, November 24, 2010
Tuesday, November 23, 2010
Shan Cha
营养功效
山楂片含多种维生素、山楂酸、酒石酸、柠檬酸、苹果酸等，还含有黄酮类、内酯、糖类、蛋白质、脂肪和钙、磷、铁等矿物质，所含的解脂酶能促进脂肪类食物的消化。促进胃液分泌和增加胃内酶素等功能。中医认为，山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈痞满、疝气血淤闭经等症。山楂中含有山萜类及黄酮类等药物成分，具有显著的扩张血管及降压作用，有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能。
适应范围
一般人皆可食用。儿童、老年人、消化不良尤其适合食用。伤风感冒、消化不良、食欲不振、儿童软骨缺钙症、儿童缺铁性贫血者可多食山楂片。
山楂片含多种维生素、山楂酸、酒石酸、柠檬酸、苹果酸等，还含有黄酮类、内酯、糖类、蛋白质、脂肪和钙、磷、铁等矿物质，所含的解脂酶能促进脂肪类食物的消化。促进胃液分泌和增加胃内酶素等功能。中医认为，山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈痞满、疝气血淤闭经等症。山楂中含有山萜类及黄酮类等药物成分，具有显著的扩张血管及降压作用，有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能。
适应范围
一般人皆可食用。儿童、老年人、消化不良尤其适合食用。伤风感冒、消化不良、食欲不振、儿童软骨缺钙症、儿童缺铁性贫血者可多食山楂片。
山楂之恋
随着《山楂树之恋》的上映，山楂成为近段时间最有人气的水果之一。除了常见的消积化、收敛止痢、活血化淤，你知道山楂对女性有哪些特殊功效吗？怎样吃才能让这些功效发挥作用？1、山楂可以治疗痛经及月经不调。
由于很多痛经是由于血瘀引起的，而山楂具有活血化瘀的作用，所以对此具有一定的疗效。
饮食方案：将山楂洗净后加入适量的水，直至将山楂煮烂，加入红糖熬成稀糊状即可，经期前3-5日开始服用至经后3日为一个疗程。
2、山楂具有抗衰老的作用。
山楂的抗衰老作用居水果之首，多喝些山楂柠檬水，是最简单的美容方法了。
山楂柠檬水的做法：将柠檬片或者柠檬干与山楂一同泡入水中饮用，可以反复冲泡，需坚持饮用。
3、具有降脂减肥的作用。
山楂具有很强的助消化功能，每日坚持饮用山楂茶，还可以达到降血脂的功效。
山楂茶的做法：将山楂洗净后切开，之后根据个人口味加入冰糖，一起用沸水泡置3-5分钟就可以饮用了。
【药理作用】用于降压，调节血脂，消积食、健脾胃，行气散淤、驱绦虫；可用于肉食积滞、胃脘涨满、泻痢腹痛、瘀血经闭、产后瘀阻、高血压症；改善心肌收缩，扩张冠状血管血液流量。
Hawthorn Fruit
山楂片含多种维生素、山楂酸、酒石酸、柠檬酸、苹果酸等，还含有黄酮类、内酯、糖类、蛋白质、脂肪和钙、磷、铁等矿物质，所含的解脂酶能促进脂肪类食物的消化。促进胃液分泌和增加胃内酶素等功能。中医认为，山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈痞满、疝气血淤闭经等症。山楂中含有山萜类及黄酮类等药物成分，具有显著的扩张血管及降压作用，有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能。
【性味与归经】 酸、甘、微温。归脾、胃、肝经。
【功能与主治】 消食健胃，行气散瘀。用于肉食积滞，胃脘胀满，泻痢腹痛，瘀血经闭，产后瘀阻，心腹刺痛，疝气疼痛；高脂血症。焦山楂消食导滞作用增强。用于肉食积滞，泻痢不爽。
【性味与归经】 酸、甘、微温。归脾、胃、肝经。
【功能与主治】 消食健胃，行气散瘀。用于肉食积滞，胃脘胀满，泻痢腹痛，瘀血经闭，产后瘀阻，心腹刺痛，疝气疼痛；高脂血症。焦山楂消食导滞作用增强。用于肉食积滞，泻痢不爽。
Thursday, November 11, 2010
JPM Downgrades Shineway To Underweight Vs Neutral
JPMorgan downgrades Shineway Pharmaceutical (2877.HK) to Underweight vs Neutral after 3Q10 results show slowing growth. House expects more margin pressure as more drugs it sold added to essential drug list program starting 2011; drugs on list have to have their margins lowered. House also cuts target price to HK$20.00 vs HK$21.00 after lowering FY10-FY11 sales by 9.6%-15.8% on weak 3Q10 sales. "In our view, the margin pressure for Shineway is greater than that of its peers due to its portfolio of cheaper products and its above-average margins," says JPM. Adds, prefers United Laboratories (3933.HK) because of its exciting new product portfolio (which includes diabetic insulin) and lower risk of any margin compression that comes from new government initiatives. Shineway Pharmaceutical last down 1.2% at HK$25.55
MARKET OUTLOOK
The Federal Reserve’s new round of quantitative easing is expected to bring U.S. dollar under pressure over the next six months and increase risks of global inflation and asset bubbles in the long run. China has recently raised its key
interest rate for the first time since 2007 in order to combat inflation and rising
property prices. This move reflected a turning point of China’s monetary policy
and change in government’s top priority from “growth” to “inflation”. We expect to see more rate hikes in 2011 but the impact on stock market will be similar to the previous cycle in our view. During the period from April 2006 to October 2007, China lifted 1-year lending rate from 5.58% to 7.29% while the Shanghai SE Composite Index surged from approximately 1,400 to 6,000 and the Hang Seng Index (“HSI”) climbed from approximately 17,000 to 32,000. The possibility of a bull cycle for China and Hong Kong stock markets over the next 6 to 12 months is also supported by fundamental valuation. According to market estimates, the HSI(at 24,144)is now trading at 2010 PER of 15.3x which is close to the historical averages of 15.9x, 15.4x and 14.8x over the past 10, 20 and 30 years respectively.Obviously, current valuation of the HSI is not cheap but certainly not at a risky level. We maintain our year-end target for the HSI at 24,000-25,000 and believe the index would reach 28,000 in 2011. Any pull back should be viewed as a buying opportunity.
Chinese banking sector is our top favourite among H shares for the rest of the year because (i) third-quarter earnings of banks were largely above market expectations, (ii) further rate hikes will improve net interest margin resulting in earnings upgrade, (iii) current valuation of banks, trading at 2011 PER of 8.5x-13.0x or 10.1x on average, is still cheap by historical standard or compared with HSCEI.
Our top picks remains ICBC (1398) and CCB (939). On the other hand, we continue to take a cautious view on Chinese property stocks given unfavourable
government policies. However, those with robust property sales revenue and strong executive capability should deserve a positive re-rating such as Evergrande (3333). Our price target for Evergrande is $4.20.
Investors who prefer to trade laggards may consider the following stocks. Angang Steel’s (347) share price dropped 2% in October since the company recorded a loss in the third quarter. However, we expect earnings to make a sharp rebound in the fourth quarter amid a rise in steel price. Our price target for Angang Steel is $14.80.
SMIC (981), the largest semiconductor foundry in Mainland China, reported
better-than-expected third quarter earnings. We believe the counter deserves a positive re-rating with a price target of $0.75 based on P/B of 1.25x. New World Development (17), the smallest blue chip property company, is currently trading at a discount of 42% to NAV. Further increase in Hong Kong’s property prices will eventually trigger a re-rating of property stock with deep discount to NAV in our view. Our price target for New World Development is $19.60.
The Federal Reserve’s new round of quantitative easing is expected to bring U.S. dollar under pressure over the next six months and increase risks of global inflation and asset bubbles in the long run. China has recently raised its key
interest rate for the first time since 2007 in order to combat inflation and rising
property prices. This move reflected a turning point of China’s monetary policy
and change in government’s top priority from “growth” to “inflation”. We expect to see more rate hikes in 2011 but the impact on stock market will be similar to the previous cycle in our view. During the period from April 2006 to October 2007, China lifted 1-year lending rate from 5.58% to 7.29% while the Shanghai SE Composite Index surged from approximately 1,400 to 6,000 and the Hang Seng Index (“HSI”) climbed from approximately 17,000 to 32,000. The possibility of a bull cycle for China and Hong Kong stock markets over the next 6 to 12 months is also supported by fundamental valuation. According to market estimates, the HSI(at 24,144)is now trading at 2010 PER of 15.3x which is close to the historical averages of 15.9x, 15.4x and 14.8x over the past 10, 20 and 30 years respectively.Obviously, current valuation of the HSI is not cheap but certainly not at a risky level. We maintain our year-end target for the HSI at 24,000-25,000 and believe the index would reach 28,000 in 2011. Any pull back should be viewed as a buying opportunity.
Chinese banking sector is our top favourite among H shares for the rest of the year because (i) third-quarter earnings of banks were largely above market expectations, (ii) further rate hikes will improve net interest margin resulting in earnings upgrade, (iii) current valuation of banks, trading at 2011 PER of 8.5x-13.0x or 10.1x on average, is still cheap by historical standard or compared with HSCEI.
Our top picks remains ICBC (1398) and CCB (939). On the other hand, we continue to take a cautious view on Chinese property stocks given unfavourable
government policies. However, those with robust property sales revenue and strong executive capability should deserve a positive re-rating such as Evergrande (3333). Our price target for Evergrande is $4.20.
Investors who prefer to trade laggards may consider the following stocks. Angang Steel’s (347) share price dropped 2% in October since the company recorded a loss in the third quarter. However, we expect earnings to make a sharp rebound in the fourth quarter amid a rise in steel price. Our price target for Angang Steel is $14.80.
SMIC (981), the largest semiconductor foundry in Mainland China, reported
better-than-expected third quarter earnings. We believe the counter deserves a positive re-rating with a price target of $0.75 based on P/B of 1.25x. New World Development (17), the smallest blue chip property company, is currently trading at a discount of 42% to NAV. Further increase in Hong Kong’s property prices will eventually trigger a re-rating of property stock with deep discount to NAV in our view. Our price target for New World Development is $19.60.
Friday, November 5, 2010
四环医药控股集团有限公司 股票编号： 00460
SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. 集团网址： http://www.sihuanpharm.com
业务状况
集团简介：
－ 集团主要供应１４种药物，用於治疗心脑血管及中枢神经系统。其中「克林澳」、「安捷利」为唯一经国家药监局批准含特定活性成分的药物品牌，共占集团２００９年度及２０１０年６月止半年度总收入５７・３％及５７・７％。另亦销售仿制药及抗敏感药。
－ 於２０１０年１０月，集团拥有２支共３３３人的研发团队，成功开发１３种产品，并取得１２种产品的全国分销权。集团在中国持有９９项专利，另有２３３项专利正在申请当中，在国外有４项。大部分产品已列入国家及省级医保药品目录及国家基本药物目录，并受政府的零售价格上限管制。集团正开发逾３０种产品，包括
四种已完成或正处於临床试验阶段，预期四年内推出，其中１０种为创新药，其馀为仿制药。
－ 至２０１０年１０月止，集团分销网络覆盖３１个省市及自治区近一万家医院，占所有三级医院７０％、二级医院５５％，以及５４００家一级及其他医院与医疗机构。
－ 集团产品的主要原材料为活性药物成分，最大供应商为Ｈａｒｂｉｎ Ｔｒｉ－Ｌｉｏｎ
Ｐｈａｒｍａｃｅｕｔｉｃａｌ（主要分包制造商）及北京高博。集团与北京高博於２００９年河北省成立廊坊四环，并持５１％权益，以生产ＡＰＩ及医药中介产品等原材料。
－ 集团拥有一间克林澳ＡＰＩ生产厂、一间锅炉房及一间接待办事处（总面积为２９３２平方米）、一个扩建设施及一间口服固体药包装厂，总面积为７８２平方米（未获建设规划许可证）。集团共经营六条综合生产线, 所有生产设施均获国家药监局的ＧＭＰ认证。
业绩表现：
－ 截至２０１０年６月３０日止半年度，集团营业额上升４６・９％至４・７３亿元（人民币；下同），股东应占溢利上升１・１倍至２・５５亿元。期内业务概况如下：
（一）毛利上升４９・５％至３・４６亿元，毛利率由去年同期的７１・９％上升至７３・２％；
（二）心脑血管药物：营业额上升５４・２％至３・９３亿元，占总营业额８３％，毛利率由去年同期的
８１・８％下降至８０・６％；
（三）抗感染药物及其他药物：营业额上升１９・３％至７９７８万元，占总营业额１６・９％，毛利率由去年同期的３４・３％上升至３７％；
（四）於２０１０年６月３０日，集团之现金及现金等价物为６・２亿元；流动比率为５・１倍；集团并无任何借款。
－ ２００９年度，集团营业额上升３９％至７・０９亿元（人民币；下同），股东应占溢利上升３７・７％至３・２６亿元。年内业务概况如下：
（一）毛利上升３７・３％至５・１７亿元，毛利率由去年的７３・８％下跌至７２・９％；
（二）心脑血管药物：营业额上升３９・７％至５・６１亿元，占总营业额７９・１％，毛利率由去年的
８４・５％下降至８１・４％；
（三）抗感染药物及其他药物：营业额上升３０・７％至１・４亿元，占总营业额１９・８％，毛利率由去年的３４・２％上升至４０・８％；
（四）於２００９年１２月３１日，集团之现金及现金等价物为６・１３亿元；流动比率为３・２倍；集团并无任何借款。
发展概览
－ 於２０１０年１０月，集团业务发展策略概述如下：
（一）继续巩固心脑血管药品业务，并扩大研发团队及重点发展注射用磺西林钠及奥卡西平片。另计划於四年内推出四种药物以补充现有产品组合；
（二）拟扩展销售团队至５００人，设立更多地区办事处，拟於五年内将三级、二级、一级及其他医院的覆盖率分别提高至９０％、８０％及７０％。；
（三）透过收购、合作及合营进行扩充，计划与境外药品公司成立合营公司；及
（四）拟将生产设施升级至符合新的ＧＭＰ标准及有选择性地符合欧盟或美国ＦＤＡ标准来加强生产质量；集团现有两个已规划的生产设施。其中河北省廊坊主要生产活性药物成分，预期将於２０１１年上半年投
产。另一於北京生产冻干粉针剂及小容量注射剂，预期将於２０１２年底投产。完成后总年产能将增加１亿瓶冻干粉针剂、１０００万瓶无菌粉针剂、３亿万瓶小容量注射剂及３０吨活性药物成分。
－ ２０１０年１０月，集团发售新股上市，估计集资净额为６３・３６亿港元，拟用作以下用途：
（一）约１２・６７亿港元（占２０％）用於开发及研究抗感染、新陈代谢、心血管系统、肿瘤及神经系统等目标治疗领域新产品；
（二）约９・５亿港元（占１５％）用於收购能补充及扩展集团现有产品组合的特定产品或生产线；
（三）约９・５亿港元（占１５％）用於建设位於廊坊及北京的两项新生产设施；
（四）约１９・０１亿港元（占３０％）用於并购适当的目标公司或业务；
（五）约６・３４亿港元（占１０％）用於加大销售及分销力度；及
（六）约６・３４亿港元（占１０％）用作营运资金及一般公司开支，特别是用於应付集团业务模式变动所产生的现金流量需求增加。
股本变化
－ ２０１０年１０月，以每股＄４・６，发行及配售１２・５亿股新股上市，另超额配售１・８７５亿股。
招股书预测
－ 「预期截至２０１０年１２月３１日止年度之股东应占溢利将不少於５亿元人民币，全面摊薄每股盈利不少於人民币１０分。」
－
业务状况
集团简介：
－ 集团主要供应１４种药物，用於治疗心脑血管及中枢神经系统。其中「克林澳」、「安捷利」为唯一经国家药监局批准含特定活性成分的药物品牌，共占集团２００９年度及２０１０年６月止半年度总收入５７・３％及５７・７％。另亦销售仿制药及抗敏感药。
－ 於２０１０年１０月，集团拥有２支共３３３人的研发团队，成功开发１３种产品，并取得１２种产品的全国分销权。集团在中国持有９９项专利，另有２３３项专利正在申请当中，在国外有４项。大部分产品已列入国家及省级医保药品目录及国家基本药物目录，并受政府的零售价格上限管制。集团正开发逾３０种产品，包括
四种已完成或正处於临床试验阶段，预期四年内推出，其中１０种为创新药，其馀为仿制药。
－ 至２０１０年１０月止，集团分销网络覆盖３１个省市及自治区近一万家医院，占所有三级医院７０％、二级医院５５％，以及５４００家一级及其他医院与医疗机构。
－ 集团产品的主要原材料为活性药物成分，最大供应商为Ｈａｒｂｉｎ Ｔｒｉ－Ｌｉｏｎ
Ｐｈａｒｍａｃｅｕｔｉｃａｌ（主要分包制造商）及北京高博。集团与北京高博於２００９年河北省成立廊坊四环，并持５１％权益，以生产ＡＰＩ及医药中介产品等原材料。
－ 集团拥有一间克林澳ＡＰＩ生产厂、一间锅炉房及一间接待办事处（总面积为２９３２平方米）、一个扩建设施及一间口服固体药包装厂，总面积为７８２平方米（未获建设规划许可证）。集团共经营六条综合生产线, 所有生产设施均获国家药监局的ＧＭＰ认证。
业绩表现：
－ 截至２０１０年６月３０日止半年度，集团营业额上升４６・９％至４・７３亿元（人民币；下同），股东应占溢利上升１・１倍至２・５５亿元。期内业务概况如下：
（一）毛利上升４９・５％至３・４６亿元，毛利率由去年同期的７１・９％上升至７３・２％；
（二）心脑血管药物：营业额上升５４・２％至３・９３亿元，占总营业额８３％，毛利率由去年同期的
８１・８％下降至８０・６％；
（三）抗感染药物及其他药物：营业额上升１９・３％至７９７８万元，占总营业额１６・９％，毛利率由去年同期的３４・３％上升至３７％；
（四）於２０１０年６月３０日，集团之现金及现金等价物为６・２亿元；流动比率为５・１倍；集团并无任何借款。
－ ２００９年度，集团营业额上升３９％至７・０９亿元（人民币；下同），股东应占溢利上升３７・７％至３・２６亿元。年内业务概况如下：
（一）毛利上升３７・３％至５・１７亿元，毛利率由去年的７３・８％下跌至７２・９％；
（二）心脑血管药物：营业额上升３９・７％至５・６１亿元，占总营业额７９・１％，毛利率由去年的
８４・５％下降至８１・４％；
（三）抗感染药物及其他药物：营业额上升３０・７％至１・４亿元，占总营业额１９・８％，毛利率由去年的３４・２％上升至４０・８％；
（四）於２００９年１２月３１日，集团之现金及现金等价物为６・１３亿元；流动比率为３・２倍；集团并无任何借款。
发展概览
－ 於２０１０年１０月，集团业务发展策略概述如下：
（一）继续巩固心脑血管药品业务，并扩大研发团队及重点发展注射用磺西林钠及奥卡西平片。另计划於四年内推出四种药物以补充现有产品组合；
（二）拟扩展销售团队至５００人，设立更多地区办事处，拟於五年内将三级、二级、一级及其他医院的覆盖率分别提高至９０％、８０％及７０％。；
（三）透过收购、合作及合营进行扩充，计划与境外药品公司成立合营公司；及
（四）拟将生产设施升级至符合新的ＧＭＰ标准及有选择性地符合欧盟或美国ＦＤＡ标准来加强生产质量；集团现有两个已规划的生产设施。其中河北省廊坊主要生产活性药物成分，预期将於２０１１年上半年投
产。另一於北京生产冻干粉针剂及小容量注射剂，预期将於２０１２年底投产。完成后总年产能将增加１亿瓶冻干粉针剂、１０００万瓶无菌粉针剂、３亿万瓶小容量注射剂及３０吨活性药物成分。
－ ２０１０年１０月，集团发售新股上市，估计集资净额为６３・３６亿港元，拟用作以下用途：
（一）约１２・６７亿港元（占２０％）用於开发及研究抗感染、新陈代谢、心血管系统、肿瘤及神经系统等目标治疗领域新产品；
（二）约９・５亿港元（占１５％）用於收购能补充及扩展集团现有产品组合的特定产品或生产线；
（三）约９・５亿港元（占１５％）用於建设位於廊坊及北京的两项新生产设施；
（四）约１９・０１亿港元（占３０％）用於并购适当的目标公司或业务；
（五）约６・３４亿港元（占１０％）用於加大销售及分销力度；及
（六）约６・３４亿港元（占１０％）用作营运资金及一般公司开支，特别是用於应付集团业务模式变动所产生的现金流量需求增加。
股本变化
－ ２０１０年１０月，以每股＄４・６，发行及配售１２・５亿股新股上市，另超额配售１・８７５亿股。
招股书预测
－ 「预期截至２０１０年１２月３１日止年度之股东应占溢利将不少於５亿元人民币，全面摊薄每股盈利不少於人民币１０分。」
－
Wednesday, November 3, 2010
Shanghai Electric(2727.HK) L/T Winner.
STOCK CALL: Citigroup raises Shanghai Electric (2727.HK) target price to HK$5.50 from HK$4.00 on expectation of more profits from new energy business, overseas orders. Says company's plan to sell US$8.29 billion worth of coal-fired equipment to India's Reliance ADA Group will boost orders on hand by 28%; revenue by US$500-600 million per year (6-7% its FY09 revenue). Notes hedging has been done to mitigate yuan appreciation risk. Says new energy division remains on growth drive; expects revenue of this division would surge to CNY13.8 billion in FY11 from CNY7.9 billion in FY10, underpinned by more nuclear equipment sales. Keeps stock at Buy.
Shanghai Elec Tipped L/T Winner
Dongfang Electric (1072.HK) +3.5% at HK$41.90 on top of 7.4% rally yesterday, which came on analysts-beating 3Q results; intraday high of HK$41.90 marks fresh 52-week high. Daiwa raises Dongfang's 6-month target price to HK$44.40 from HK$38.50, keeps Buy call; says strong 3Q results "driven by strong gross-profit-margin expansion," revises up FY10-12 EPS forecasts by 6.4%-8.2% to incorporate 3Q earnings surprise. Still, despite positive view on stock intact, Daiwa believes peer Shanghai Electric (2727.HK) "may be a long-term winner" in nuclear business, given its strong positioning in AP1000 (a third-generation technology), while Dongfang has been focused mainly on CPR (a 2.5-generation technology). Shanghai Electric +3.8% at HK$5.42.
Tuesday, November 2, 2010
SH ELECTRIC 2727.HK
CLSA raises Shanghai Electric (2727.HK) target price to HK$5.60 vs HK$4.50 after lifting stock price multiple to 16X 2012 earnings based on likelihood of earnings upside, improved earnings visibility. Says new orders reinforce house preference for company over Dongfang Electric (1072.HK). "We expect that the valuation gap with Dongfang Electric will narrow, and it remains our top pick among the equipment suppliers." says CLSA. Adds, Shanghai Electric currently trading on 13.4X FY12 P/E vs Dongfang Electric's 20X FY12 suppliers. Keeps stock at Buy. Shares last +3.8% at HK$4.89, but off early high of HK$5.06, after announcing US$8.3 billion order with India's Reliance ADA Group
Subscribe to:
Posts (Atom)